Nutriband (NASDAQ:NTRB) Rating Lowered to "Sell" at Wall Street Zen

Key Points

• Nutriband's stock rating was downgraded from "hold" to "sell" by Wall Street Zen, adding to a previous downgrade from Zacks Research to "strong sell."
• The company's recent quarterly earnings report showed a loss of ($2.12) EPS, missing estimates significantly and raising concerns over its negative return on equity of 85.40%.
• Nutriband currently has a market capitalization of $87.34 million with an average target price of $13.00, indicating potential volatility in its stock performance.

Nutriband (NASDAQ:NTRB - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Friday.

Separately, Zacks Research downgraded shares of Nutriband from a "hold" rating to a "strong sell" rating in a report on Tuesday, September 16th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $13.00.

Nutriband Stock Performance

NTRB stock traded up $0.09 during trading on Friday, reaching $7.26. The company had a trading volume of 16,733 shares, compared to its average volume of 34,806. Nutriband has a twelve month low of $3.72 and a twelve month high of $11.78. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.70 and a current ratio of 4.78. The company has a market cap of $87.34 million, a price-to-earnings ratio of -2.53 and a beta of 1.13. The firm has a 50-day simple moving average of $6.96 and a 200-day simple moving average of $6.73.

Nutriband (NASDAQ:NTRB - Get Free Report) last posted its quarterly earnings results on Tuesday, September 9th. The company reported ($2.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($1.95). The business had revenue of $0.62 million for the quarter, compared to analysts' expectations of $0.71 million. Nutriband had a negative return on equity of 85.40% and a negative net margin of 398.29%. As a group, sell-side analysts expect that Nutriband will post -0.6 earnings per share for the current year.

Institutional Trading of Nutriband

A hedge fund recently bought a new stake in Nutriband stock. US Bancorp DE acquired a new stake in Nutriband Inc. (NASDAQ:NTRB - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,798 shares of the company's stock, valued at approximately $29,000. Institutional investors and hedge funds own 19.70% of the company's stock.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.